Topical Infliximab in Autoimmune Eyes With Keratoprosthesis
Status:
Withdrawn
Trial end date:
2017-04-03
Target enrollment:
Participant gender:
Summary
The Boston Keratoprosthesis type I (KPro) is a prosthetic cornea used to treat several causes
of corneal blindness. Some categories of patients, including those with auto-immune diseases
such as Stevens-Johnson syndrome, toxic epidermal necrolysis syndrome and mucous membrane
pemphigoid, have a higher risk of failure for the KPro. Because of chronic inflammation, the
cornea supporting the KPro may melt, leading to a higher risk of infection, loss of the KPro
and loss of the eye.
Infliximab is an antibody against tumor necrosis factor alpha and is used intravenously to
control inflammation in several diseases. It has been used in some cases of corneal melting
with significant success.
This study's hypothesis is that infliximab can be successfully used as an eye drop (instead
of the usual administration through veins) and that its regular use may prevent melt in eyes
with a Boston Keratoprosthesis type I and underlying auto-immune disease.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
James Chodosh, MD, MPH Massachusetts Eye and Ear Infirmary